Related Experiment Video
Updated: Sep 23, 2026
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Relationship between the expression levels of CD61, CD63, and PAC-1 on platelet surface in peripheral blood and the
1Department of Urology, Chaoyang Hospital, Capital Medical University, Beijing, China.
Insights
Platelet activation markers CD61, CD63, and PAC-1 are elevated in renal transplant patients with acute rejection. Anticoagulant therapy improved graft function and survival rates in these patients.
Area of Science:
- Nephrology
- Immunology
- Transplantation Medicine
Background:
- Platelet activation plays a role in transplant outcomes.
- Biomarkers of platelet activation require further investigation in renal transplantation.
Purpose of the Study:
- To investigate the association between platelet surface markers (CD61, CD63, PAC-1) and renal transplant complications.
- To evaluate the impact of anticoagulant therapy on graft function and survival in patients with acute rejection.
Main Methods:
- Flow cytometry was used to measure CD61, CD63, and PAC-1 expression on platelets in 86 renal transplant patients.
- Patients were categorized into groups with normal graft function, acute rejection, or acute tubular necrosis.
- Acute rejection patients received either anticoagulant therapy or no treatment.
Main Results:
- Elevated CD61, CD63, and PAC-1 expression was observed in patients with acute rejection compared to other groups.
- Anticoagulant therapy in acute rejection patients led to decreased expression of these markers.
- Patients receiving anticoagulant therapy showed improved graft function recovery and higher 1-year survival rates.
Conclusions:
- Pre-transplant platelet activation, indicated by CD61, CD63, and PAC-1 levels, is linked to acute rejection, not acute tubular necrosis.
- Anticoagulant therapy offers significant benefits for renal transplant recipients experiencing acute rejection.
Objective:
To analyze the relationships between the expression levels of CD61, CD63, and PAC-1 on the platelet surface and the incidences of acute rejection and tubular necrosis as well as the recovery of graft function after renal transplantation.
Methods:
The expression levels of CD61, CD63, and PAC-1 on platelet surfaces were assayed by flow cytometry in 86 patients with different stages of uremia before and after transplantation. Patients were divided into three groups: 29 patients with normal graft function, 30 with acute rejection, and 27 with acute tubular necrosis. Patients with acute rejection were randomly assigned into groups treated with or without anticoagulants.
Results:
The expression levels of CD61, CD63, and PAC-1 on platelet surfaces significantly increased (P <.05) among patients with acute rejection, as compared with those with normal graft function or acute tubular necrosis. Compared with controls, the expression levels of CD61, CD63, and PAC-1 were lower among acute rejection patients who, received anticoagulant therapy. The recovery time for graft function shorter and, the 1-year patients and graft survival rates higher.
Conclusions:
The pretransplant expression levels of CD61, CD63, and PAC-1 on platelet surface were significantly higher among patients with acute rejection, suggesting that this complication rather than acute tubular necrosis may be related to platelet activation. Patients with acute rejection displayed benefit from anticoagulant therapy.
